SG11201909590XA - Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine - Google Patents
Dementia therapeutic agent combining pyrazoloquinoline derivative and memantineInfo
- Publication number
- SG11201909590XA SG11201909590XA SG11201909590XA SG11201909590XA SG 11201909590X A SG11201909590X A SG 11201909590XA SG 11201909590X A SG11201909590X A SG 11201909590XA SG 11201909590X A SG11201909590X A SG 11201909590XA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic agent
- memantine
- agent combining
- dementia therapeutic
- pyrazoloquinoline derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
ABSfRACT There is provided a therapeutic agent for Alzheimer's disease for combined use of (S)-(2-methoxy-3,5-dimethylpyridin-4-y1)-1-(telmhydrofuran-3-y1)-1H-pyrazolo[4,3-c]qui noline-4(5H)-one represented by formula (1): 0 or a pharmaceutically acceptable salt thereof, and meniantine represented by formula (II): NH 2 ( H ) or a pharmaceutically acceptable salt thereof. 19
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762513754P | 2017-06-01 | 2017-06-01 | |
PCT/JP2018/020649 WO2018221550A1 (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909590XA true SG11201909590XA (en) | 2019-11-28 |
Family
ID=64454745
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202113199RA SG10202113199RA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
SG11201909590X SG11201909590XA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202113199RA SG10202113199RA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
Country Status (12)
Country | Link |
---|---|
US (1) | US11147803B2 (en) |
EP (1) | EP3632437B1 (en) |
JP (1) | JP7177772B2 (en) |
KR (1) | KR102627790B1 (en) |
CN (1) | CN110603039B (en) |
AU (1) | AU2018276568A1 (en) |
BR (1) | BR112019023595A2 (en) |
CA (1) | CA3060183A1 (en) |
IL (1) | IL270394B (en) |
MX (1) | MX2019013383A (en) |
SG (2) | SG10202113199RA (en) |
WO (1) | WO2018221550A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10202113198TA (en) | 2017-06-01 | 2021-12-30 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
TWI784006B (en) | 2017-06-01 | 2022-11-21 | 日商衛材R&D企管股份有限公司 | Therapeutic agent for Lewis disease containing pyrazoloquinoline derivative |
CN110545812A (en) | 2017-06-01 | 2019-12-06 | 卫材R&D管理有限公司 | Pharmaceutical compositions comprising PDE9 inhibitors |
AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
CN114524827A (en) * | 2022-02-22 | 2022-05-24 | 深圳市儿童医院 | Pyrazole derivative for treating severe nervous disease and application thereof |
CN114524828A (en) * | 2022-02-22 | 2022-05-24 | 深圳市儿童医院 | Thiazole derivative for treating severe nervous disease and application thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5318759A (en) | 1976-08-02 | 1978-02-21 | Nisshin Oil Mills Ltd | Method of making fried beancurd |
JPH05132484A (en) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | Pyrazoloquinoline and pyrazolonaphthylidene derivative |
BR9507672A (en) | 1994-05-24 | 1997-08-19 | Hoffmann La Roche | Tricyclic derivatives of dicarbonyl |
HN2002000317A (en) | 2001-11-02 | 2003-05-21 | Pfizer | PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS |
JP2005534713A (en) | 2002-08-07 | 2005-11-17 | 三菱ウェルファーマ株式会社 | Dihydropyrazolopyridine compounds |
DE10238722A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives |
DE102004004142A1 (en) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines |
RU2426734C2 (en) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Pyrazolopyridines and analogues thereof |
WO2005118583A1 (en) | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
JP2006045118A (en) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | New pyrazoloquinolone derivative |
CN101268073B (en) | 2005-09-15 | 2011-10-19 | Aska制药株式会社 | Heterocyclic compound, and production process and use thereof |
EP2489667B1 (en) | 2006-12-13 | 2015-04-15 | ASKA Pharmaceutical Co., Ltd. | Quinoxaline derivative |
KR20090097918A (en) | 2006-12-13 | 2009-09-16 | 아스카 세이야쿠 가부시키가이샤 | Therapeutic agent for urinary tract disease |
JP4579346B2 (en) | 2007-05-11 | 2010-11-10 | ファイザー・インク | Amino heterocyclic compounds |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
MX2011002340A (en) | 2008-09-08 | 2011-04-04 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of cns disorders. |
TWI404721B (en) | 2009-01-26 | 2013-08-11 | Pfizer | Amino-heterocyclic compounds |
JP5609861B2 (en) | 2009-03-05 | 2014-10-22 | アステラス製薬株式会社 | Quinoxaline compounds |
AP2011005819A0 (en) | 2009-03-31 | 2011-08-31 | Boehringer Ingelheim Int | 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators. |
US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
JP2012005157A (en) | 2010-06-14 | 2012-01-05 | Seiko Epson Corp | Method of manufacturing laminated component |
JP5756176B2 (en) | 2010-08-12 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 6-Cycloalkyl-1,5-dihydro-pyrazolo (3,4-D) pyrimidi-4-one derivatives and their use as PDE9A inhibitors |
JP5888237B2 (en) | 2010-09-07 | 2016-03-16 | アステラス製薬株式会社 | Pyrazoloquinoline compounds |
US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
EP2573073B1 (en) | 2011-09-26 | 2014-10-22 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
JP6042060B2 (en) | 2011-09-26 | 2016-12-14 | サノフイ | Pyrazoloquinolinone derivatives, their preparation and therapeutic use |
WO2013051639A1 (en) * | 2011-10-07 | 2013-04-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pyrazoloquinoline derivative |
CN105121440B (en) * | 2013-04-05 | 2017-05-24 | 卫材R&D管理有限公司 | Salt of pyrazoloquinoline derivative, and crystal thereof |
CN110545812A (en) | 2017-06-01 | 2019-12-06 | 卫材R&D管理有限公司 | Pharmaceutical compositions comprising PDE9 inhibitors |
TWI784006B (en) | 2017-06-01 | 2022-11-21 | 日商衛材R&D企管股份有限公司 | Therapeutic agent for Lewis disease containing pyrazoloquinoline derivative |
SG10202113198TA (en) | 2017-06-01 | 2021-12-30 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
CN108563565B (en) | 2018-04-08 | 2021-12-17 | 中国人民解放军海军工程大学 | Method for establishing reliability quantitative analysis model of flight landing guidance system |
-
2018
- 2018-05-30 IL IL270394A patent/IL270394B/en unknown
- 2018-05-30 JP JP2019521250A patent/JP7177772B2/en active Active
- 2018-05-30 MX MX2019013383A patent/MX2019013383A/en unknown
- 2018-05-30 CA CA3060183A patent/CA3060183A1/en active Pending
- 2018-05-30 WO PCT/JP2018/020649 patent/WO2018221550A1/en active Application Filing
- 2018-05-30 KR KR1020197033123A patent/KR102627790B1/en active IP Right Grant
- 2018-05-30 SG SG10202113199RA patent/SG10202113199RA/en unknown
- 2018-05-30 AU AU2018276568A patent/AU2018276568A1/en active Pending
- 2018-05-30 CN CN201880030140.XA patent/CN110603039B/en active Active
- 2018-05-30 SG SG11201909590X patent/SG11201909590XA/en unknown
- 2018-05-30 BR BR112019023595-7A patent/BR112019023595A2/en unknown
- 2018-05-30 US US16/607,459 patent/US11147803B2/en active Active
- 2018-05-30 EP EP18808870.2A patent/EP3632437B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20200010219A (en) | 2020-01-30 |
RU2019135838A (en) | 2021-07-13 |
KR102627790B1 (en) | 2024-01-23 |
US11147803B2 (en) | 2021-10-19 |
US20200129488A1 (en) | 2020-04-30 |
MX2019013383A (en) | 2020-02-20 |
SG10202113199RA (en) | 2021-12-30 |
IL270394B (en) | 2022-08-01 |
EP3632437B1 (en) | 2024-03-13 |
JP7177772B2 (en) | 2022-11-24 |
CA3060183A1 (en) | 2018-12-06 |
EP3632437A1 (en) | 2020-04-08 |
BR112019023595A2 (en) | 2020-05-26 |
IL270394A (en) | 2020-02-27 |
AU2018276568A1 (en) | 2019-11-07 |
RU2019135838A3 (en) | 2021-09-29 |
EP3632437A4 (en) | 2021-03-17 |
CN110603039A (en) | 2019-12-20 |
WO2018221550A1 (en) | 2018-12-06 |
JPWO2018221550A1 (en) | 2020-04-02 |
CN110603039B (en) | 2023-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909590XA (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine | |
SG11201909595VA (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil | |
JOP20190076B1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
MX2022000244A (en) | PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF. | |
PH12019500776A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
NZ766835A (en) | Pharmaceutical compounds | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
MX2019013397A (en) | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative. | |
PL1663244T3 (en) | Pteridine derivatives for the treatment of tnf-alpha-related diseases. | |
MX2018012211A (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders. | |
MX2019006612A (en) | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS. | |
JOP20190233A1 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
MX2018012208A (en) | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders. | |
PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
MX2021010122A (en) | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders. | |
MX2020002630A (en) | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS. | |
MX2019013198A (en) | Pharmaceutical composition comprising pde9 inhibitor. | |
MX2021007247A (en) | Rapamycin derivatives. | |
MX2023001071A (en) | Treatment of migraine. | |
SA519401827B1 (en) | Pyrido[3,4-D]Pyrimidine Derivative and Pharmaceutically Acceptable Salt Thereof | |
MX2018011592A (en) | Compound having mutant idh inhibitory activity, preparation method and use thereof. | |
MX2019004602A (en) | Anti-proliferative agents for treating pah. | |
PH12020551772A1 (en) | Oxo-substituted compound | |
ZA202200331B (en) | Naltrexone formulation | |
MX2022000729A (en) | Combination therapy for cancer treatment. |